Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Bimekizumab in Psoriatic Arthritis (Open-Label Extension)
2017-001003-74Phase 2Completed
- Sponsor
- UCB
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Primary endpoint: Incidence of Adverse Events. Started Aug 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-001003-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001003-74.